OBJECTIVES: to estimate medical, social and economic effectiveness of treatment of children with the Non-Hodgkin lymphomas (NHLs) according to the NHL-BFM-95 protocol. METHODS: The study included 62 children with NHL, 50 of them with B-cell lymphomas, and 12 with T-cell lymphomas. All children received treatment according to the NHL-BFM-95 protocol. Eighteen children, 12 boys and 6 girls, entered a study group aimed at estimating gained years of quality-adjusted life years. As of January 1st, 2010 the follow-up period comprised 13 years. Survival rates were estimated using the Kaplan–Meier method. RESULTS: A 5-year event-free survival of patients treated according to the NHL-BFM-95 protocol for patients with B-cell and T-cell lymphomas was 0,81±0,08 and 0,54±0,14 respectively. Chemotherapy complications appear to be the main reason for mortality during program treatment which is a rate of controlled mortality correlating with the quality of the accompanying treatment. The assumed number of quality-adjusted life years were estimated for each of the patients considering the known disease outcome. A total of 657 years of quality-adjusted life years were saved for 18 patients with NHL treated according to the NHL-BFM-95 protocol; therefore the average rate is 36,5 years. This rate could be used for cost-effectiveness analysis of treatment as a proof of expensive treatment advisability for society from cost perspective. In 2009, the Republic children’s clinical hospital (Izhevsk) conducted a survey on clinico-economic cost of treatment of children with NHL according to the NHL-BFM-95 protocol. The cost of one patient illness appeared to be US$29,550. The method of cost-effectiveness analysis on this medical technology with the calculation of saved years of employability and GDP produced during this time ( US$1356 estimated ) demonstrates its social effectiveness. CONCLUSIONS: The performed clinoco-economic analysis proves medical, social and economic effectiveness of treatment of children with NHL according to the NHL-BFM-95 protocol.